Husch Blackwell’s Intellectual Property team is full service with nationally recognized practitioners across all areas of IP, including prosecution and litigation. With approximately 100 lawyers who devote significant time to IP matters, our team is comparable to a mid-sized IP boutique and is one of the largest such teams in the Midwestern U.S. Within our geographic footprint, we are the firm of choice for a number of large and emerging businesses.
Barnes & Thornburg’s Intellectual Property Department is among the largest in the country, with nearly 100 IP attorneys and professionals. We have more than 65 registered patent attorneys and agents all with technical degrees, including several Ph.Ds. Our practice covers a broad spectrum of services, including strategic IP portfolio services, prosecuting and litigating patents, trademarks and copyrights, enforcement of patents and trademarks and defense of IP enforcement actions. From coast to coast, we counsel clients from a variety of industries, such as medical device, plastics and packaging, internet and computer technology, food and beverage, pharmaceutical, automotive and aviation. With decades of experience, we understand that the many types of IP assets drive core business strategy and brand development. Our cost-conscious solutions help clients derive as much value from their intellectual resources as from their human resources.
Green, Griffith & Borg-Breen LLP is a preeminent boutique intellectual property law firm, focusing on pharmaceuticals, chemistry and biotechnology—specializing in litigation. Our attorneys share decades of experience partnering with both brand and generic companies to navigate the most complex IP and related FDA issues, including the Hatch-Waxman Act.
Acknowledged leaders in our field, we help clients build and execute targeted, timely and cost-effective IP strategies from project initiation through litigation, with an eye toward securing market position and overcoming obstacles to new product entry. Our range of services includes counseling regarding strategic formulation, portfolio and due diligence, as well as handling all stages of trial and appeals concerning IP and related FDA issues affecting 505(b)(1), 505(b)(2) and ANDA applications, and their related drug products and therapies.
Each of our attorneys have extensive scientific backgrounds—many with Ph.D.s-- that permit exploration of technical solutions at a deep level. This expertise, coupled with our unparalleled experience litigating at the PTO and in the federal courts, positions us to work with each client to craft and execute the best strategy to attain our clients’ goals.
Our extensive experience, technical expertise, big picture vision, and integrated strategy consistently produce favorable outcomes for companies developing, protecting, and commercializing their products, processes and therapies. Visit: www.greengriffith.com to learn more.